Navigation Links
Amsterdam Molecular Therapeutics Reports Full Year Results 2009
Date:2/24/2010

AMSTERDAM, February 24, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year to December 31, 2009.

    Highlights
    - Glybera(R) Marketing Authorisation Application submitted to
      European Medicines Agency (EMA, formerly known as EMEA);
    - EMA commenced formal review of Glybera(R) dossier on January
      20, 2010;
    - EMA grants orphan drug designation for AMT's Acute
      Intermittent Porphyria ("AIP") program;
    - EMA grants orphan drug designation for AMT's Duchenne
      Muscular Dystrophy ("DMD") program;
    - SenterNovem awards EUR 4 million investment credit for the
      development of AMT's DMD program;
    - Raised EUR 5 million convertible loan notes, which convert
      into ordinary shares at EUR 3.91 per share;
    - New management team.

Jorn Aldag, Chief Executive Officer of AMT, commented: "In 2009 we announced a rebalancing of our strategy, focused on our lead product Glybera(R), a proprietary product for lipoprotein lipase deficiency (LPLD), together with the ongoing development of four earlier stage progams targeting:
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
2. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
3. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
5. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
6. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
7. Amsterdam Molecular Therapeutics Part of Next Biotech Index
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
11. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... Ontario (PRWEB) May 21, 2015 ... into an exclusive North American distribution agreement with ... testing system. , With more than 160 years ... products and services for laboratory and production facilities, ... operational excellence and differentiated services to enable science. ...
(Date:5/20/2015)... This year has been one of the ... Patented Pearl’s Premium Ultra Low Maintenance Lawn Seed comes ... are coming out of record bad weather. Offering ... global concerns related to water, health, and climate change, ... to the standard, water-wasting, chemical-treated standard lawn. Many ...
(Date:5/20/2015)... , May 20, 2015  Health eCareers, ... short-staffed healthcare organizations with job seekers looking for ... , a new mobile and online tool dedicated ... healthcare industry. SHIFT enables employers to ... tenens, travel nursing, per diem and other temporary ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
... , GAITHERSBURG, Md., Aug. 6 GenVec, Inc. (Nasdaq: ... quarter ended June 30, 2009. , , ... GenVec reported a net loss of $4.8 million ($0.05 per ... net loss of $6.6 million ($0.08 per share) in the comparable quarter ...
... , ROCKVILLE, Md., Aug. 6 Novavax, Inc. ... Frederick W. Driscoll as Vice President, Chief Financial Officer and ... Novavax,s President and Chief Executive Officer. , , ... President and Chief Executive Officer of Genelabs Technologies, Inc. ...
... , NEWTON, Mass., Aug. 6 Microfluidics International ... release second quarter 2009 financial results on Tuesday, August 11, ... , Michael C. Ferrara, President and Chief Executive Officer, ... Officer, will host a conference call and live audio webcast at ...
Cached Biology Technology:GenVec Reports Second Quarter 2009 Financial Results 2GenVec Reports Second Quarter 2009 Financial Results 3GenVec Reports Second Quarter 2009 Financial Results 4GenVec Reports Second Quarter 2009 Financial Results 5GenVec Reports Second Quarter 2009 Financial Results 6GenVec Reports Second Quarter 2009 Financial Results 7Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer 2Microfluidics International Corporation to Report Second Quarter 2009 Financial Results on August 11, 2009 2
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... at The University of Queensland could contribute to the ... virus and Dengue fever. Led by Associate ... School of Molecular and Microbial Sciences identified a novel ... belong. The team found all flaviviruses produced ...
... Harbor, N.Y. Much like cancer cells, plant cells ... milieu, in culture dishes, have highly unstable genomes. Changes ... cells cope with challenging culture conditions but inadvertently also ... of DNA that can jump around in the genome, ...
... can have genetic causes. Researchers at the Institute of ... correlation. The causes of what is known as irritable ... of the gastrointestinal tract, are considered unclear making ... which were published in the prestigious jour-nal " Human ...
Cached Biology News:UQ research targets West Nile virus and dengue fever 2CSHL researchers map changing epigenetic modifications that enable transposons to run amok 2Irritable bowel syndrome can have genetic causes 2
... are used to study co-translational and ... events such as signal peptide cleavage, ... can be examined by the translation ... in the presence of these microsomal ...
... using Mo Bio luciferase assay. Mo Bio Laboratories ... will allow you to certify your products ATP-Free ... you to deliver them to your customers in ... limit is 3.5 x 10-12 /l, which will ...
... Microarrays: Biomedical Photometrics Inc. (Waterloo, Ontario, Canada) ... have collaborated to develop a fluorescence reader ... The DNAscope AT is based on BPIs ... automatically reads up to six ArrayTubes in ...
... Sciences provides a comprehensive kinase analysis ... substrate (PKS) peptide microarrays synthesized on ... kinase profiling, quantitative measurement of kinase ... This comprehensive service includes preparation of ...
Biology Products: